Private Trust Company’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$991K Sell
6,324
-70
-1% -$10.5K 0.08% 279
2026
Q1
$977K Buy
6,394
+108
+2% +$16.6K 0.09% 260
2025
Q4
$867K Buy
6,286
+206
+3% +$27K 0.08% 289
2025
Q3
$780K Buy
6,080
+189
+3% +$23.1K 0.07% 310
2025
Q2
$713K Buy
5,891
+357
+6% +$40.2K 0.07% 311
2025
Q1
$617K Buy
5,534
+358
+7% +$38.1K 0.06% 331
2024
Q4
$504K Buy
5,176
+355
+7% +$37.9K 0.05% 376
2024
Q3
$555K Buy
4,821
+355
+8% +$40.3K 0.06% 361
2024
Q2
$475K Sell
4,466
-638
-13% -$64K 0.05% 384
2024
Q1
$494K Buy
5,104
+12
+0.2% +$1.23K 0.05% 363
2023
Q4
$514K Buy
5,092
+465
+10% +$44.9K 0.06% 335
2023
Q3
$471K Sell
4,627
-148
-3% -$15K 0.06% 329
2023
Q2
$482K Buy
4,775
+664
+16% +$66.4K 0.06% 325
2023
Q1
$378K Buy
4,111
+663
+19% +$57.9K 0.05% 379
2022
Q4
$313K Sell
3,448
-166
-5% -$14K 0.05% 405
2022
Q3
$275K Sell
3,614
-216
-6% -$17.9K 0.04% 411
2022
Q2
$324K Sell
3,830
-220
-5% -$19.3K 0.05% 373
2022
Q1
$355K Sell
4,050
-95
-2% -$8.22K 0.06% 271
2021
Q4
$363K Sell
4,145
-272
-6% -$22.6K 0.05% 301
2021
Q3
$361K Buy
4,417
+1,122
+34% +$101K 0.05% 313
2021
Q2
$301K Sell
3,295
-148
-4% -$13.2K 0.05% 335
2021
Q1
$294K Sell
3,443
-160
-4% -$14.4K 0.05% 340
2020
Q4
$340K Buy
3,603
+500
+16% +$43.7K 0.06% 290
2020
Q3
$269K Sell
3,103
-1,684
-35% -$146K 0.05% 306
2020
Q2
$423K Buy
4,787
+1,479
+45% +$128K 0.09% 240
2020
Q1
$272K Buy
3,308
+71
+2% +$6.33K 0.07% 278
2019
Q4
$306K Buy
3,237
+21
+0.7% +$1.88K 0.06% 304
2019
Q3
$279K Sell
3,216
-280
-8% -$25.1K 0.06% 304
2019
Q2
$319K Sell
3,496
-79
-2% -$6.69K 0.06% 283
2019
Q1
$307K Buy
3,575
+9
+0.3% +$723 0.06% 291
2018
Q4
$274K Sell
3,566
-55
-2% -$4.28K 0.07% 288
2018
Q3
$279K Sell
3,621
-240
-6% -$17.7K 0.06% 310
2018
Q2
$261K Buy
3,861
+183
+5% +$12.6K 0.06% 319
2018
Q1
$266K Buy
3,678
+538
+17% +$41K 0.06% 312
2017
Q4
$236K Buy
3,140
+49
+2% +$3.7K 0.05% 327
2017
Q3
$237K Buy
+3,091
New +$233K 0.05% 333
2017
Q1
Sell
-3,292
Closed -$214K 368
2016
Q4
$214K Sell
3,292
-184
-5% -$11.9K 0.05% 301
2016
Q3
$245K Buy
3,476
+241
+7% +$17.6K 0.06% 281
2016
Q2
$239K Buy
3,235
+53
+2% +$3.66K 0.06% 275
2016
Q1
$206K Buy
3,182
+255
+9% +$17.3K 0.06% 286
2015
Q4
$225K Buy
2,927
+236
+9% +$18.7K 0.06% 278
2015
Q3
$221K Buy
2,691
+67
+3% +$5.96K 0.07% 280
2015
Q2
$231K Sell
2,624
-216
-8% -$19.8K 0.07% 288
2015
Q1
$250K Buy
2,840
+17
+0.6% +$1.51K 0.07% 279
2014
Q4
$234K Buy
2,823
+63
+2% +$5.22K 0.07% 259
2014
Q3
$233K Sell
2,760
-79
-3% -$6.39K 0.08% 259
2014
Q2
$230K Hold
2,839
0.07% 269
2014
Q1
$216K Sell
2,839
-3,674
-56% -$268K 0.08% 239
2013
Q4
$469K Sell
6,513
-190
-3% -$13.2K 0.19% 127
2013
Q3
$461K Sell
6,703
-5,007
-43% -$331K 0.21% 123
2013
Q2
$742K Buy
+11,710
New +$762K 0.34% 80

Other funds holding NVS

Private Trust Company's NVS Position: Q2 2026 in Review

Private Trust Company reduced its Novartis (NVS) stake by 1.1% in Q2 2026, selling an estimated $10.5K and leaving 6,324 shares worth $991K. The position accounts for 0.08% of the portfolio, ranked #279.

Private Trust Company first reported a position in NVS in Q2 2013 and has held it in 51 quarters since. 1,617 funds tracked by Wall St. Rank hold NVS as of Q2 2026.

  • Private Trust Company held 6,324 shares of Novartis worth $991K as of Q2 2026.
  • Private Trust Company sold 70 Novartis shares in Q2 2026, an estimated $10.5K.
  • Novartis made up 0.08% of Private Trust Company's portfolio in Q2 2026, its #279 holding.
  • Private Trust Company first reported a position in Novartis in Q2 2013 and has held it in 51 quarters since.
  • 1,617 funds tracked by Wall St. Rank held Novartis as of Q2 2026.

Based on Private Trust Company's 13F filing for Q2 2026, filed 28 Jul 2026.